Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Melanoma 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Gemcitabine 20Cisplatin 13Paclitaxel 8Carboplatin 8Docetaxel 5Radiotherapy 4Doxorubicin 4aflibercept 3Vinblastine 3Ramucirumab 3Methotrexate 3Fluorouracil 3vinflunine 2pembrolizumab 2Trastuzumab 2Sunitinib 2Platinum 2Neoadjuvant Therapy 2Ifosfamide 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tipifarnib 1temsirolimus 1rubitecan 1piritrexim 1pegfilgrastim 1pazopanib 1lonafarnib 1ixabepilone 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urethral Neoplasms × ALT-801 × Clear all
NCT01326871 2024-06-25

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Altor BioScience

Phase 1/2 Completed
68 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡